[克唑替尼：终于用于晚期ALK重排非小细胞肺癌的一线治疗] - Suppr

[Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].

作者信息

Giroux Leprieur Etienne, Wislez Marie

机构信息

AP-HP, hôpital Ambroise-Paré, service de pneumologie et oncologie thoracique, 9, avenue Charles-de-Gaulle, 92100 Boulogne-Billancourt, France; Université Paris-Saclay, UVSQ, laboratoire EA4340, biomarqueurs en cancérologie et onco-hématologie, 9, avenue Charles-de-Gaulle, 92100 Boulogne-Billancourt, France.

AP-HP, hôpital Tenon, service de pneumologie, 4, rue de la Chine, 75020 Paris, France; Sorbonne universités, UPMC université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France.

出版信息

Bull Cancer. 2016 Feb;103(2):125-6. doi: 10.1016/j.bulcan.2015.12.002. Epub 2016 Jan 25.

DOI:10.1016/j.bulcan.2015.12.002

PMID:26822904

Abstract

摘要

相似文献

[Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].

Bull Cancer. 2016 Feb;103(2):125-6. doi: 10.1016/j.bulcan.2015.12.002. Epub 2016 Jan 25.

Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.

J Thorac Oncol. 2012 Mar;7(3):623-5. doi: 10.1097/JTO.0b013e318241daab.

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.

Lung Cancer. 2015 Feb;87(2):89-95. doi: 10.1016/j.lungcan.2014.12.010. Epub 2014 Dec 18.

Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.

Ann Pharmacother. 2013 Feb;47(2):189-97. doi: 10.1345/aph.1R002. Epub 2013 Feb 5.

U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.

Clin Cancer Res. 2014 Apr 15;20(8):2029-34. doi: 10.1158/1078-0432.CCR-13-3077. Epub 2014 Feb 26.

Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.

Genomics. 2013 Sep;102(3):157-62. doi: 10.1016/j.ygeno.2013.02.006. Epub 2013 Feb 20.

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90.

Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.

J Thorac Oncol. 2014 Dec;9(12):e86-7. doi: 10.1097/JTO.0000000000000358.

Treatment and detection of ALK-rearranged NSCLC.

Lung Cancer. 2013 Aug;81(2):145-54. doi: 10.1016/j.lungcan.2013.03.017. Epub 2013 Jun 12.

ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?

Expert Rev Anticancer Ther. 2015 Feb;15(2):225-33. doi: 10.1586/14737140.2014.986103. Epub 2014 Nov 21.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

[Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].

Bull Cancer. 2016 Feb;103(2):125-6. doi: 10.1016/j.bulcan.2015.12.002. Epub 2016 Jan 25.

Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.

J Thorac Oncol. 2012 Mar;7(3):623-5. doi: 10.1097/JTO.0b013e318241daab.

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.

Lung Cancer. 2015 Feb;87(2):89-95. doi: 10.1016/j.lungcan.2014.12.010. Epub 2014 Dec 18.

Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.

Ann Pharmacother. 2013 Feb;47(2):189-97. doi: 10.1345/aph.1R002. Epub 2013 Feb 5.

U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.

Clin Cancer Res. 2014 Apr 15;20(8):2029-34. doi: 10.1158/1078-0432.CCR-13-3077. Epub 2014 Feb 26.

Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.

Genomics. 2013 Sep;102(3):157-62. doi: 10.1016/j.ygeno.2013.02.006. Epub 2013 Feb 20.

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90.

Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.

J Thorac Oncol. 2014 Dec;9(12):e86-7. doi: 10.1097/JTO.0000000000000358.

Treatment and detection of ALK-rearranged NSCLC.

Lung Cancer. 2013 Aug;81(2):145-54. doi: 10.1016/j.lungcan.2013.03.017. Epub 2013 Jun 12.

ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?

Expert Rev Anticancer Ther. 2015 Feb;15(2):225-33. doi: 10.1586/14737140.2014.986103. Epub 2014 Nov 21.

[Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].

作者信息

Giroux Leprieur Etienne, Wislez Marie

机构信息

AP-HP, hôpital Tenon, service de pneumologie, 4, rue de la Chine, 75020 Paris, France; Sorbonne universités, UPMC université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France.

出版信息

Bull Cancer. 2016 Feb;103(2):125-6. doi: 10.1016/j.bulcan.2015.12.002. Epub 2016 Jan 25.

DOI:10.1016/j.bulcan.2015.12.002

PMID:26822904

Abstract

摘要

[Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].

作者信息

机构信息

出版信息

相似文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

[Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].

作者信息

机构信息

出版信息